Compounded Semaglutide vs Ozempic: What You Need to Know

Compounded semaglutide is a version of the same active ingredient (semaglutide) that is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk (the maker of Ozempic and Wegovy). Compounding pharmacies create these formulations under FDA-regulated frameworks, typically as 503A (patient-specific) or 503B (outsourcing facility) operations.

Key distinctions:

• Same active molecule — Compounded semaglutide uses the same peptide sequence as brand-name products.
• Different formulation — Compounded versions may use different excipients, concentrations, or delivery methods (e.g., sublingual instead of injectable).
• Regulatory pathway — Compounded products are not FDA-approved as finished drugs but are prepared under FDA-regulated compounding frameworks.
• Availability — Compounded semaglutide became widely available during brand-name shortages under FDA shortage provisions.

Cost is the primary driver of interest in compounded semaglutide. The price difference is substantial:

• Brand-name Ozempic/Wegovy — $800 to $1,500 per month without insurance. Even with insurance, copays can range from $25 to $300+ depending on plan coverage and tier.
• Compounded semaglutide — $200 to $400 per month through telehealth providers and compounding pharmacies. Some programs offer additional discounts for multi-month commitments.

This represents a 60-80% cost reduction compared to brand-name products. For patients without insurance coverage for GLP-1 medications — which remains common — compounded options provide a dramatically more accessible price point.

However, it is important to note that pricing for compounded products can vary significantly between providers. Patients should compare total costs including consultation fees, shipping, and any required follow-up visits.

Quality is the most important consideration when evaluating compounded semaglutide:

• Brand-name advantages — Ozempic and Wegovy undergo extensive FDA approval processes including large-scale clinical trials, rigorous manufacturing standards (cGMP), and ongoing post-market surveillance.
• Compounding quality — Legitimate 503B outsourcing facilities operate under FDA inspection and must follow cGMP guidelines. 503A pharmacies are state-regulated with less federal oversight.
• Purity concerns — High-quality compounding pharmacies test for purity, potency, sterility, and endotoxins. However, not all compounders maintain equal standards.
• Bioequivalence — Compounded products are not required to demonstrate bioequivalence to brand-name drugs through clinical trials.

The FDA has issued warnings about some low-quality compounded semaglutide products, including those containing salt forms (semaglutide sodium) that differ from the base form used in approved products. Patients should verify their compounder uses semaglutide base, not alternative salt forms.

The right choice depends on individual circumstances:

Brand-name may be better if:

• Insurance covers the medication with reasonable copay
• You prefer the established clinical trial data behind approved products
• You want the convenience of pre-filled injection pens
• Your provider specifically recommends the brand-name version

Compounded may be better if:

• Brand-name products are unaffordable without insurance
• Supply shortages make brand-name versions unavailable
• You have access to a reputable 503B compounding pharmacy
• Your provider is experienced with compounded GLP-1 medications

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication, including semaglutide in any form.